Imunon, Inc. Research and Development in Process
Imunon, Inc. (IMNN) reported Research and Development in Process of $2.40 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2020-03-25
- Imunon, Inc. research and development in process for fiscal 2019 was $2.40M, a 0.00% change from fiscal 2018.
- Imunon, Inc. research and development in process for fiscal 2018 was $2.40M.
| Period end | Research and Development in Process 12 month |
|---|---|
| 2019-12-31 | $2.40M 10-K · filed 2020-03-25 |
| 2018-12-31 | $2.40M 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |